Cerenome sets sights on 2027 randomised trial after small early REYOBIQ safety dataset
Early data from ten patients give Cerenome a first case for taking its radiotherapy REYOBIQ into a randomised study next year, though the product has no commercial path yet.
Cerenome, Inc. has put a first set of human data behind its plan for a randomised mid-stage trial of REYOBIQ (rhenium Re186 obisbemeda), an investigational radiotherapy delivered into the brain's fluid spaces for patients whose solid-tumour cancers have spread to the leptomeninges. The company announced the results on 16 November 2026. They were shown as a poster at the Society for Neuro-Oncology annual meeting three days earlier.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Cerenome, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.